The next HPV vaccine approved in the United States, called Cervarix, is a bivalent vaccine that protects against HPV types 16 and 18 and was approved for use in females ages 9 to 26. Gardasil 9 ...

Gardasil-9 and Cervarix. Gardasil-9, which protects against nine types of HPV, is available for men and women, between the ages of nine and 45. Cervarix, approved for women aged nine to 45 ...

There are currently three types of HPV vaccines available: Gardasil 9, Gardasil, and Cervarix. Gardasil 9 protects against nine of the most common HPV strains, offering up to 90% protection ...

Gardasil is approved by the FDA for girls and women ages 9 to 26. The CDC and the American ... There's a second vaccine in the works: Cervarix, from GlaxoSmithKline. Cervarix targets two HPV ...

The first vaccine used was GlaxoSmithKline's Cervarix, which was replaced by MSD's Gardasil in 2012. The research by King's College London is the first direct evidence that HPV vaccination makes a ...

Cervarix: population analyzed in this table were seronegative to HPV-16 and -18, and PCR DNA negative to 14 high-risk HPV types at study entry. Gardasil: population analyzed in this table were ...

Gardasil ® (Merck) and Cervarix ® (GSK) have been positively evaluated in women up to 55 years of age. They are inducing robust responses in HIV-positive individuals. Gardasil has been used for ...

Nearly 90 per cent of cases of cervical cancer are caused by the human papillomavirus (HPV), which spreads primarily through ...

On the plus side, if GSK can show that Cervarix offers a more durable response than Gardasil, it could make substantial inroads into the latter's market share. As the vaccines market continues to ...